Clinical data | |
---|---|
Trade names | Maxalt, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601109 |
License data | |
Pregnancy category | |
Routes of administration | By mouth |
Drug class | Triptan |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 45% |
Protein binding | 14% |
Metabolism | by monoamine oxidase |
Elimination half-life | 2–3 hours |
Excretion | 82% urine; 12% faeces |
Identifiers | |
| |
Chemical and physical data | |
Formula | C15H19N5 |
Molar mass | 269.352 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Rizatriptan, sold under the brand name Maxalt among others, is a medication used for the treatment of migraine headaches.[2] It should be used as soon as the headache starts.[3] It is taken by mouth.[2]
Common side effects include chest pain, dizziness, dry mouth, and tingling.[2] Other side effects may include myocardial infarction, stroke, high blood pressure, serotonin syndrome, and anaphylaxis.[2] Excessive use may result in medication overuse headaches.[2] Use is not recommended during pregnancy and breastfeeding is not recommended within 24 hours after taking a dose.[3] Rizatriptan is in the triptan class and is believed to work by activating the 5-HT1 receptor.[2]
Rizatriptan was patented in 1991 and came into medical use in 1998.[4] It is available as a generic medication.[3] A dose in the United Kingdom costs the NHS about 3.10 £ as of 2019.[3] In the United States the wholesale cost of this amount is about US$0.73.[5] In 2017, it was the 204th most commonly prescribed medication in the United States, with more than two million prescriptions.[6][7]
References
edit- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 20 October 2020. Retrieved 7 September 2020.
- ^ a b c d e f "Rizatriptan Benzoate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 23 October 2020. Retrieved 18 March 2019.
- ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 473. ISBN 9780857113382.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 9783527607495. Archived from the original on 2019-03-06. Retrieved 2019-03-02.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
- ^ "Rizatriptan Benzoate - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.